Drug intelligence / Profile preview

XRx-225

Development stage: Preclinical
Lead developer: XORTX Therapeutics

Overview

XRx-225 is a pharmaceutical drug being developed by XORTX Therapeutics for the treatment of type 2 diabetic nephropathy. The drug was licensed from Richard Johnson and Takahiko Nakagawa and is part of XORTX's clinical development pipeline, which has received funding through various public offerings to advance its programs.

Targets

XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on XRx-225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XRx-225.

Explore the full profile